Literature DB >> 19101897

Mutations of RAS gene family in specimens of bladder cancer.

Navaz Karimianpour1, Parisa Mousavi-Shafaei, Abed-Ali Ziaee, Mohammad Taghi Akbari, Gholamreza Pourmand, Amirreza Abedi, Ali Ahmadi, Hossein Afshin Alavi.   

Abstract

INTRODUCTION: Studies have shown different types of RAS mutations in human bladder tumors with a wide range of mutation frequencies in different patient populations. This study aimed to assess the frequency of specific-point mutations in the RAS gene family of a group of Iranian patients with bladder cancer.
MATERIALS AND METHODS: We examined the tumor specimens of 35 consecutive patients with transitional cell carcinoma. The DNA samples were evaluated for the occurrence of HRAS, KRAS, and NRAS activation using a polymerase chain reaction-restriction fragment length polymorphism technique.
RESULTS: None of the patients had mutations in the RAS gene family "hot spots" including codons 12, 13, and 61.
CONCLUSION: We failed to find RAS mutations in our bladder tumor samples. These observations may reflect the involvement of different etiological factors in the induction of bladder tumor of which RAS mutation might not be present in all populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101897

Source DB:  PubMed          Journal:  Urol J        ISSN: 1735-1308            Impact factor:   1.510


  10 in total

1.  Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Authors:  Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Methylation pattern of oncogene HRAS gene promoter region and its clinical relevance to urocystic tumorigenesis.

Authors:  Xiao-Feng Sun; Lan Li; Xiu-Juan Li; Wei Shen
Journal:  Mol Biol Rep       Date:  2012-06-19       Impact factor: 2.316

Review 3.  Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.

Authors:  David J McConkey; Sangkyou Lee; Woonyoung Choi; Mai Tran; Tadeusz Majewski; Sooyong Lee; Arlene Siefker-Radtke; Colin Dinney; Bogdan Czerniak
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

4.  Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.

Authors:  Kelly M Quesnelle; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2011-07-26       Impact factor: 12.531

5.  A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

Authors:  Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith
Journal:  Cancer       Date:  2014-05-06       Impact factor: 6.860

6.  Genetic aberrations of the K-ras proto-oncogene in bladder cancer in relation to pesticide exposure.

Authors:  Diaa A Hameed; Heba A Yassa; Michael N Agban; Randa T Hanna; Ahmed M Elderwy; Mohamed A Zwaita
Journal:  Environ Sci Pollut Res Int       Date:  2018-04-12       Impact factor: 4.223

7.  The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.

Authors:  Slah Ouerhani; Karim Bougatef; Ismail Soltani; Amel Ben Ammar Elgaaied; Salem Abbes; Samia Menif
Journal:  Mol Biol Rep       Date:  2013-05-03       Impact factor: 2.316

8.  Roles of Signal Transducer Pathways in Investigation of Biopsies from Patients with Bladder Tumors

Authors:  Aysegul Bayrak; Sukru Palanduz; Ender Coskunpinar; Oner Sanli; Abdullah Armagan; Serkan Karakus; Ramazan Topaktas; Kivanc Cefle; Sukru Ozturk; Ali Ucur
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01

9.  The impact of genetic variants in the CYP2C8 gene on bladder cancer susceptibility.

Authors:  Weixing Qu; Fuzhou Zhang; Yongyi Cheng; Jing Li; Jiancheng Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-28       Impact factor: 6.055

10.  Polymorphic variants of H-RAS protooncogene and their possible role in bladder cancer etiology.

Authors:  Magdalena Traczyk; Edyta Borkowska; Marek Rożniecki; Rafał Purpurowicz; Adam Jędrzejczyk; Piotr Marks; Michał Pietrusiński; Zbigniew Jabłonowski; Marek Sosnowski; Bogdan Kałużewski
Journal:  Cent European J Urol       Date:  2012-06-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.